LOGIN  |  REGISTER
C4 Therapeutics

Stryker to announce financial results for its fourth quarter and full year 2023

January 05, 2024 | Last Trade: US$359.66 7.45 -2.03

Portage, Michigan, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for fourth quarter and full year 2023 on Tuesday, January 30, 2024.  A press release will be issued at approximately 4:05pm ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company’s fourth quarter and full year 2023, that ended December 31, 2023.

Stryker will host a webcast at 4:30pm ET on Tuesday, January 30, 2024, to discuss results for its fourth quarter and full year 2023.  The webcast can be accessed at Stryker - Events & Presentations.  An archive of the webcast will also be available on the company's website two hours after the live call ends.

About Stryker

Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.

Contacts

For investor inquiries please contact:
Jason Beach, Vice President, Investor Relations at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it. 

For media inquiries please contact:
Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB